Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.
The University of Texas MD Anderson Cancer Center today announced licensing agreements with BostonGene Corporation and Tempus for the MD Anderson EGFR Classification, which groups EGFR mutations in non-small cell lung cancer (NSCLC) based on structural modifications and sensitivity to available therapies.
Treatment for lung cancer is rapidly evolving, with new technologies and research-proven procedures.
A new research paper was published in Genes & Cancer on December 14, 2022, entitled, "Slit2 signaling stimulates Ewing sarcoma growth."
Lung cancer is the deadliest cancer in the United States and around the world. Many of the currently available therapies have been ineffective, leaving patients with very few options.
Choosing the appropriate timing for specialized palliative care can have a positive impact on life expectancy for patients with small cell lung cancer. This is the result of a recently internationally published study by the Karl Landsteiner University of Health Sciences (KL Krems, Austria). There, the relevant data of 152 patients were evaluated at the Krems University Hospital.
Surgery, especially surgery to remove cancerous tumors, relies on a range of tools and techniques as well as on the skill of the surgeon.
The developing human lung has been mapped in unprecedented detail, identifying 144 cell states in the early stages of life, and uncovering new links between developmental cells and lung cancer.
A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers from Penn Medicine's Abramson Cancer Center showed, suggesting the drug is a strong candidate for clinical trials.
New research from the University of Colorado (CU) Cancer Center highlights the need for additional data collection for women hoping to have successful pregnancies while undergoing treatment for lung cancer.
Regular postsurgical screening is critical for patients with lung cancer, the United States' second most prevalent type of cancer and leading cause of cancer deaths.
In many cancer types, cancer cells try to survive by escaping attack from the immune system. These cancer cells hijack mechanisms called immune checkpoints to trick the immune system into thinking they are healthy cells.
A new molecular imaging radiotracer can precisely diagnose a variety of cancers, providing a roadmap to identify patients who may benefit from targeted radionuclide therapies.
Immune checkpoint inhibitors such as Keytruda and Opdivo work by unleashing the immune system's T cells to attack tumor cells.
Scientists investigating the mechanics of the early stages of lung cancer have identified a new potential treatment, which could also aid early detection of the disease.
A new study has revealed significant racial disparities in how quickly minorities with the most common form of lung cancer receive potentially lifesaving radiation therapy compared with their white counterparts.
A recent study posted to the bioRxiv* preprint server reported the interaction between monkeypox and human cells. Molecular sequences were screened to identify differentially expressed genes (DEGs) and their associated signal pathway, expression regulation, and metabolic pathways.
Small cell lung cancer is a particularly aggressive tumor, which has so far been treated with standardized measures.
Newly released results from the Phase III ADAURA trial reveal that osimertinib yielded a 5.5-year median disease-free survival in the post-surgical treatment of patients with EGFR-mutated lung cancer, and nearly three in four patients treated with adjuvant osimertinib were disease-free at four years.
The TIMP-1 protein levels in both tissues and blood have been repeatedly associated with a poor prognosis in lung cancers, but its role in this cancer process was, to date, unknown.
A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and development of therapies, according to late-breaking data [to be] reported at the ESMO Congress 2022 by scientists of the Francis Crick Institute and University College London, funded by Cancer Research UK. The particles, which are typically found in vehicle exhaust and smoke from fossil fuels, are associated with non-small cell lung cancer (NSCLC) risk, accounting for over 250,000 lung cancer deaths globally per year.